Stephen Christopher Zambrzycki

Dr. Stephen Christopher Zambrzycki

Medical University of South Carolina, Charleston, Illinois, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
SVSerena Vickers
Serena Vickers
MBMatthew Bernier
Matthew Bernier
Stephen Christopher ZambrzyckiStephen Christopher Zambrzycki
Stephen Christopher Zambrzycki
Facundo M. FernándezFacundo M. Fernández
Facundo M. Fernández
PNPaul Newton
Paul Newton
CCCeline Caillet
Celine Caillet
Background Poor quality medicines have devastating consequences. A plethora of innovative portable devices to screen for poor quality medicines has become available, leading to hope that they could empower medicine inspectors and enhance surveillance. However, information comparing these new technologies is woefully scarce. Methods We undertook a systematic review of Embase, PubMed, Web of Science and SciFinder databases up to 30 April 2018. Scientific studies evaluating the performances/abilities of portable devices to assess any aspect of the quality of pharmaceutical products were included. Results Forty-one devices, from small benchtop spectrometers to ‘lab-on-a-chip’ single-use devices, with prices ranging from US$20 000, were included. Only six devices had been field-tested (GPHF-Minilab, CD3/CD3+, TruScan RM, lateral flow dipstick immunoassay, CBEx and Speedy Breedy). The median (range) number of active pharmaceutical ingredients (APIs) assessed per device was only 2 (1–20). The majority of devices showed promise to distinguish genuine from falsified medicines. Devices with the potential to assay API (semi)-quantitatively required consumables and were destructive (GPHF-Minilab, PharmaChk, aPADs, lateral flow immunoassay dipsticks, paper-based microfluidic strip and capillary electrophoresis), except for spectroscopic devices. However, the 10 spectroscopic devices tested for their abilities to quantitate APIs required processing complex API-specific calibration models. Scientific evidence of the ability of the devices to accurately test liquid, capsule or topical formulations, or to distinguish between chiral molecules, was limited. There was no comment on cost-effectiveness and little information on where in the pharmaceutical supply chain these devices could be best deployed. Conclusion Although a diverse range of portable field detection devices for medicines quality screening is available, there is a vitally important lack of independent evaluation of the majority of devices, particularly in field settings. Intensive research is needed in order to inform national medicines regulatory authorities of the optimal choice of device(s) to combat poor quality medicines.

27 October 2017 in Analytical Chemistry
Verified
Journal Article
Closed access
JKJoel D. Keelor
Joel D. Keelor
Stephen Christopher ZambrzyckiStephen Christopher Zambrzycki
Stephen Christopher Zambrzycki
ALAnyin Li
Anyin Li
BCBrian H. Clowers
Brian H. Clowers
Facundo M. FernándezFacundo M. Fernández
Facundo M. Fernández

8 March 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
MAMehak Arora
Mehak Arora
Stephen Christopher ZambrzyckiStephen Christopher Zambrzycki
Stephen Christopher Zambrzycki
JLJoshua Levy
Joshua Levy
AEAnnette Esper
Annette Esper
JFJennifer Koren Frediani
Jennifer Koren Frediani
Rishikesan KamaleswaranRishikesan Kamaleswaran
Rishikesan Kamaleswaran
Point-of-care screening tools are essential to expedite patient care and decrease reliance on slow diagnostic tools (e.g., microbial cultures) to identify pathogens and their associated antibiotic resistance. Analysis of volatile organic compounds (VOC) emitted from biological media has seen increased attention in recent years as a potential non-invasive diagnostic procedure. This work explores the use of solid phase micro-extraction (SPME) and ambient plasma ionization mass spectrometry (MS) to rapidly acquire VOC signatures of bacteria and fungi. The MS spectrum of each pathogen goes through a preprocessing and feature extraction pipeline. Various supervised and unsupervised machine learning (ML) classification algorithms are trained and evaluated on the extracted feature set. These are able to classify the type of pathogen as bacteria or fungi with high accuracy, while marked progress is also made in identifying specific strains of bacteria. This study presents a new approach for the identification of pathogens from VOC signatures collected using SPME and ambient ionization MS by training classifiers on just a few samples of data. This ambient plasma ionization and ML approach is robust, rapid, precise, and can potentially be used as a non-invasive clinical diagnostic tool for point-of-care applications.

30 September 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Stephen Christopher ZambrzyckiStephen Christopher Zambrzycki
Stephen Christopher Zambrzycki
CCCeline Caillet
Celine Caillet
SVSerena Vickers
Serena Vickers
MBMarcos Bouza
Marcos Bouza
DDDavid V. Donndelinger
David V. Donndelinger
Facundo M. FernándezFacundo M. Fernández
Facundo M. Fernández
Background: Post-market surveillance is a key regulatory function to prevent substandard and falsified (SF) medicines from being consumed by patients. Field deployable technologies offer the potential for rapid objective screening for SF medicines.Methods and findings: We evaluated twelve devices: three near infrared spectrometers (MicroPHAZIR RX, NIR-S-G1, Neospectra 2.5), two Raman spectrometers (Progeny, TruScan RM), one mid-infrared spectrometer (4500a), one disposable colorimetric assay (Paper Analytical Devices, PAD), one disposable immunoassay (Rapid Diagnostic Test, RDT), one portable liquid chromatograph (C-Vue), one microfluidic system (PharmaChk), one mass spectrometer (QDa), and one thin layer chromatography kit (GPHF-Minilab). Each device was tested with a series of field collected medicines (FCM) along with simulated medicines (SIM) formulated in a laboratory. The FCM and SIM ranged from samples with good quality active pharmaceutical ingredient (API) concentrations, reduced concentrations of API (80% and 50% of the API), no API, and the wrong API. All the devices had high sensitivities (91.5 to 100.0%) detecting medicines with no API or the wrong API. However, the sensitivities of each device towards samples with 50% and 80% API varied greatly, from 0% to 100%. The infrared and Raman spectrometers had variable sensitivities for detecting samples with 50% and 80% API (from 5.6% to 50.0%). The devices with the ability to quantitate API (C-Vue, PharmaChk, QDa) had sensitivities ranging from 91.7% to 100% to detect all poor quality samples. The specificity was lower for the quantitative C-Vue, PharmaChk, & QDa (50.0% to 91.7%) than for all the other devices in this study (95.5% to 100%).Conclusions: The twelve devices evaluated could detect medicines with the wrong or none of the APIs, consistent with falsified medicines, with high accuracy. However, API quantitation to detect formulations similar to those commonly found in substandards proved more difficult, requiring further technological innovation.

1 March 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
ALAnyin Li
Anyin Li
MPMartin R. L. Paine
Martin R. L. Paine
Stephen Christopher ZambrzyckiStephen Christopher Zambrzycki
Stephen Christopher Zambrzycki
RSRachel B. Stryffeler
Rachel B. Stryffeler
JWJason Wu
Jason Wu
Facundo M. FernándezFacundo M. Fernández
Facundo M. Fernández

30 September 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
CCCeline Caillet
Celine Caillet
SVSerena Vickers
Serena Vickers
VVVayouly Vidhamaly
Vayouly Vidhamaly
KBKem Boutsamay
Kem Boutsamay
PBPhonepasith Boupha
Phonepasith Boupha
PNPaul Newton
Paul Newton
Céline Caillet and co-authors discuss a Collection on use of portable devices for the evaluation of medicine quality and legitimacy.